- Home
- CHRS vs HGLB Comparison
CHRS vs HGLB Comparison
Compare CHRS & HGLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HGLB
- Stock Information
- Founded
- CHRS 2010
- HGLB 1998
- Country
- CHRS United States
- HGLB United States
- Employees
- CHRS 235
- HGLB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HGLB Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- HGLB Finance
- Exchange
- CHRS Nasdaq
- HGLB Nasdaq
- Market Cap
- CHRS 134.4M
- HGLB 176.4M
- IPO Year
- CHRS 2014
- HGLB N/A
- Fundamental
- Price
- CHRS $1.21
- HGLB $7.94
- Analyst Decision
- CHRS Strong Buy
- HGLB
- Analyst Count
- CHRS 4
- HGLB 0
- Target Price
- CHRS $5.38
- HGLB N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- HGLB 91.8K
- Earning Date
- CHRS 03-12-2025
- HGLB 01-01-0001
- Dividend Yield
- CHRS N/A
- HGLB 13.16%
- EPS Growth
- CHRS N/A
- HGLB N/A
- EPS
- CHRS N/A
- HGLB N/A
- Revenue
- CHRS $304,340,000.00
- HGLB N/A
- Revenue This Year
- CHRS $2.47
- HGLB N/A
- Revenue Next Year
- CHRS N/A
- HGLB N/A
- P/E Ratio
- CHRS N/A
- HGLB N/A
- Revenue Growth
- CHRS 44.19
- HGLB N/A
- 52 Week Low
- CHRS $0.66
- HGLB $6.42
- 52 Week High
- CHRS $2.87
- HGLB $9.45
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- HGLB 65.85
- Support Level
- CHRS $1.03
- HGLB $7.72
- Resistance Level
- CHRS $1.23
- HGLB $7.95
- Average True Range (ATR)
- CHRS 0.13
- HGLB 0.13
- MACD
- CHRS -0.02
- HGLB 0.02
- Stochastic Oscillator
- CHRS 38.89
- HGLB 96.43
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.